XORTX Therapeutics Inc (TSE:XRTX) has released an update.
XORTX Therapeutics Inc. announced a key study presentation at the American Society of Nephrology’s Kidney Week, exploring the effects of xanthine oxidase on polycystic kidney disease. The study highlights the role of xanthine oxidase inhibitors in reducing cyst growth and the progression of kidney disease, offering new insights into potential treatments. Investors may find this development promising as it underscores XORTX’s commitment to innovative kidney disease therapies.
For further insights into TSE:XRTX stock, check out TipRanks’ Stock Analysis page.
